Cognoa's Canvas Dx product is authorized by the Food and Drug Administration and assists healthcare providers in diagnosing autism spectrum disorder for children ages 18 months through 72 months. Members of Health Transformation Alliance can now add Canvas Dx to their benefit plans.
The system, developed by digital health startup Cognoa, uses information from questionnaires and videos to help pediatricians diagnose autism. It received marketing authorization from the FDA on Wednesday.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Digital therapeutics clinical trials enable collection and analysis of data in real time, but considerations like standardization of analysis, trial endpoints and placebo controls are critical, experts at the DTx East conference in Boston said.
The startup previously developed the Sleepio application, which is targeted at insomnia, and is offered to around 12 million users through partnerships with payers and employers like Boston Medical Center, Comcast and the NHS.
By teaming up, SAP employees will be able to use Cognoa's app to screen their children for developmental delays in language, behavior and other areas.
Existing Cognoa investor Morningside, a private equity and venture capital firm, provided the new funding.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Measuring lung function, enhancing fetal monitoring and tissue engineering took the top three prizes at second edition of Impact Pediatric Pitch. But of the digital health technologies on display, machine learning was a big theme.